Richard Brudnick

Richard Brudnick is the current Chief Business Officer and Head of Strategy at Codiak BioSciences, a position they have held since June 2018. Prior to joining Codiak, Richard was a Partner at Israel Biotech Fund, and before that, they served as CBO at VolitionRx.

Richard has over 15 years of experience in the biotech and pharmaceutical industries, with a focus on business development, strategy, and finance. Richard has played a key role in the development and commercialization of several groundbreaking new treatments, including exosome therapeutics.

Under Richard's leadership, Codiak has become a world leader in exosome research and development, with a proprietary platform that can engineer exosomes to have precise and intentionally chosen properties. This cutting-edge technology is being used to develop novel treatments for a wide range of diseases, with the potential to transform the lives of millions of patients worldwide.

Richard Brudnick has a SM from the MIT Sloan School of Management and an SB from the Massachusetts Institute of Technology, both in Management Science.

Their manager is Keith Gottesdiener, President & CEO. Some of their coworkers include Carman Alenson - CAO & SVP, Finance, Jeremy Duffield - CSO, and Ann Lee - CTO.